MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Adamas Pharmaceuticals Company Profile (NASDAQ:ADMS)

Consensus Ratings for Adamas Pharmaceuticals (NASDAQ:ADMS) (?)
Ratings Breakdown: 1 Hold Rating(s), 7 Buy Rating(s)
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $34.13 (108.33% upside)

Analysts' Ratings History for Adamas Pharmaceuticals (NASDAQ:ADMS)
Show:
DateFirmActionRatingPrice TargetActions
5/12/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2016MizuhoLower Price TargetNeutral$17.00 -> $16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/1/2016JMP SecuritiesInitiated CoverageOutperform$29.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/26/2016AegisReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/12/2016Piper JaffrayReiterated RatingOverweight$37.00 -> $44.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/31/2015Credit SuisseReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/29/2015Needham & Company LLCReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/11/2015William BlairReiterated RatingOutperform$35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/28/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha